

Adults Hospitalized With Pneumonia in the United States: Trends and Mortality

Clinical Infectious Diseases

65, 1806-1812

DOI: [10.1093/cid/cix647](https://doi.org/10.1093/cid/cix647)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Disease burden of hospitalized community-acquired pneumonia in South Korea. <i>Medicine (United States)</i> , 2018, 97, 100-107.	1.0	31
2	Development and Validation of a Natural Language Processing Tool to Identify Patients Treated for Pneumonia across VA Emergency Departments. <i>Applied Clinical Informatics</i> , 2018, 09, 122-128.	1.7	30
3	How can we improve clinical research in pneumonia?. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 220-226.	2.6	1
4	Genetic cartography of longevity in humans and mice: Current landscape and horizons. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2718-2732.	3.8	27
5	Future Research Directions in Pneumonia. NHLBI Working Group Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 256-263.	5.6	54
6	Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age. <i>Expert Review of Vaccines</i> , 2018, 17, 45-55.	4.4	12
7	Sepsis and community-acquired pneumonia. <i>Annals of Research Hospitals</i> , 2018, 0, 2, 7-7.	0.0	17
8	Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. <i>Annals of Research Hospitals</i> , 2018, 0, 2, 1-1.	0.0	25
9	Diagnostic approach to pleural effusions. <i>AME Medical Journal</i> , 2018, 3, 116-116.	0.4	4
11	One-year mortality among hospital survivors of cholinesterase inhibitor poisoning based on Taiwan National Health Insurance Research Database from 2003 to 2012. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 72.	2.4	7
12	Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 733-752.	2.1	21
13	Adjunctive Therapies for Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 753-764.	2.1	9
14	Disease Burden and Etiologic Distribution of Community-Acquired Pneumonia in Adults: Evolving Epidemiology in the Era of Pneumococcal Conjugate Vaccines. <i>Infection and Chemotherapy</i> , 2018, 50, 287.	2.3	14
15	Community-acquired pneumonia as an emergency condition. <i>Current Opinion in Critical Care</i> , 2018, 24, 531-539.	3.2	41
16	Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. <i>BMC Infectious Diseases</i> , 2018, 18, 677.	2.9	34
17	Moving Past the Routine Use of Macrolides—Reviewing the Role of Combination Therapy in Community-Acquired Pneumonia. <i>Current Infectious Disease Reports</i> , 2018, 20, 45.	3.0	4
18	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. <i>Clinical Infectious Diseases</i> , 2018, 67, 1498-1506.	5.8	98
19	Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1147.	4.1	34

#	ARTICLE	IF	CITATIONS
20	In-Hospital Deaths Among Adults With Community-Acquired Pneumonia. <i>Chest</i> , 2018, 154, 628-635.	0.8	28
21	Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 35.	2.9	29
22	Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 187.	1.8	70
23	Community-acquired Pneumonia and Acute Respiratory Distress Syndrome: Prevalence, Risk, and Prognosis. <i>Clinical Pulmonary Medicine</i> , 2018, 25, 100-106.	0.3	1
24	Clinical Approach to Community-acquired Pneumonia. <i>Journal of Thoracic Imaging</i> , 2018, 33, 273-281.	1.5	11
25	The change in age distribution of CAP population in Korea with an estimation of clinical implications of increasing age threshold of current CURB65 and CRB65 scoring system. <i>PLoS ONE</i> , 2019, 14, e0219367.	2.5	1
26	Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. <i>Clinical Infectious Diseases</i> , 2019, 69, S33-S39.	5.8	11
27	Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0220204.	2.5	61
28	Predicting the need for ICU admission in community-acquired pneumonia. <i>Respiratory Medicine</i> , 2019, 155, 61-65.	2.9	10
29	Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia. <i>Clinical Therapeutics</i> , 2019, 41, 2540-2548.	2.5	7
30	Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old. <i>BMC Health Services Research</i> , 2019, 19, 585.	2.2	36
31	The Clinical Utility of Chest Radiography for Identifying Pneumonia: Accounting for Diagnostic Uncertainty in Radiology Reports. <i>American Journal of Roentgenology</i> , 2019, 213, 1207-1212.	2.2	27
32	Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. <i>Vaccine</i> , 2019, 37, 6201-6207.	3.8	87
33	New perspectives in aspiration community acquired Pneumonia. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 991-1002.	3.1	18
34	Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. <i>Vaccine</i> , 2019, 37, 6310-6316.	3.8	43
35	Regular cannabis use, with and without tobacco co-use, is associated with respiratory disease. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107557.	3.2	40
36	Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 841-849.	3.3	29
37	Diagnostic accuracy of chest ultrasound in patients with pneumonia in the intensive care unit: A single-hospital study. <i>Health Science Reports</i> , 2019, 2, e102.	1.5	19

#	ARTICLE	IF	CITATIONS
38	Azithromycin plus β -lactam versus levofloxacin plus β -lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 1012-1018.	1.7	4
39	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. <i>Vaccine</i> , 2019, 37, 3352-3361.	3.8	54
40	Environmental factors which can affect the burden of pneumococcal disease and the immune response to pneumococcal vaccines: the need for more precisely delineated vaccine recommendations. <i>Expert Review of Vaccines</i> , 2019, 18, 587-596.	4.4	5
41	Inflammatory responses relate to distinct bronchoalveolar lavage lipidome in community-acquired pneumonia patients: a pilot study. <i>Respiratory Research</i> , 2019, 20, 82.	3.6	17
42	Latin American Adult Immunisation Advocacy Summit: Overcoming regional barriers to adult vaccination. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 339-344.	2.9	5
43	<i>Streptococcus pneumoniae</i> : Invasion and Inflammation. <i>Microbiology Spectrum</i> , 2019, 7, .	3.0	93
44	Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. <i>Expert Review of Vaccines</i> , 2019, 18, 327-341.	4.4	35
45	Measuring the in-hospital costs of <i>Pseudomonas aeruginosa</i> pneumonia: methodology and results from a German teaching hospital. <i>BMC Infectious Diseases</i> , 2019, 19, 1028.	2.9	19
46	Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes. <i>Clinical Infectious Diseases</i> , 2019, 69, 1218-1225.	5.8	12
47	The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 139-152.	2.5	92
48	Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community-acquired pneumonia. <i>Journal of Internal Medicine</i> , 2019, 285, 635-652.	6.0	26
49	Decision-making for PCV in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 584-593.	3.3	8
50	Epidemiology of lower respiratory tract infections in adults. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 63-77.	2.5	38
51	Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 5-15.	4.4	21
52	Factors associated with hospitalization for community-acquired pneumonia in home health care patients in Taiwan. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 149-155.	2.9	9
53	Impact of Multiple Texture-Modified Diets on Oral Intake and Nutritional Status in Older Patients with Pneumonia: A Retrospective Cohort Study. <i>Dysphagia</i> , 2020, 35, 574-582.	1.8	11
54	A Reappraisal of Streptococcal Urinary Antigen Testing for Antibiotic Stewardship. <i>Clinical Infectious Diseases</i> , 2020, 71, 1435-1437.	5.8	3
55	Incidence and Mortality of Adults Hospitalized With Community-Acquired Pneumonia According to Clinical Course. <i>Chest</i> , 2020, 157, 34-41.	0.8	29

#	ARTICLE	IF	CITATIONS
56	Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. <i>Thorax</i> , 2020, 75, 38-49.	5.6	75
57	Frontline Science: Rev-Erb α links blue light with enhanced bacterial clearance and improved survival in murine <i>Klebsiella pneumoniae</i> pneumonia. <i>Journal of Leukocyte Biology</i> , 2020, 107, 11-25.	3.3	12
58	Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes. <i>Clinical Microbiology and Infection</i> , 2020, 26, 220-226.	6.0	19
59	Serum human neutrophil lipocalin: An effective biomarker for diagnosing bacterial infections. <i>Clinical Biochemistry</i> , 2020, 75, 23-29.	1.9	13
60	Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1007-1014.	2.6	25
61	Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. <i>Vaccine</i> , 2020, 38, 1770-1777.	3.8	25
62	Unraveling the Pneumonia Burden Associated With Human Metapneumovirus Infection. <i>Clinical Infectious Diseases</i> , 2020, 72, 118-120.	5.8	1
63	Predictive value of the Canada Acute Coronary Syndrome risk score for post-acute myocardial infarction infection. <i>European Journal of Internal Medicine</i> , 2020, 71, 57-61.	2.2	14
64	Rates of hospitalization for community-acquired pneumonia among US adults: A systematic review. <i>Vaccine</i> , 2020, 38, 741-751.	3.8	37
65	Factors predicting in-hospital mortality among patients admitted with community acquired pneumonia at a tertiary care hospital Karachi, Pakistan. <i>Clinical Respiratory Journal</i> , 2020, 14, 328-334.	1.6	6
66	Vaccine Effectiveness Against Influenza-Associated Lower Respiratory Tract Infections in Hospitalized Adults, Louisville, Kentucky, 2010–2013. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa262.	0.9	9
67	Etiology of community-acquired pneumonia in adults: a systematic review. <i>Pneumonia (Nathan Qld)</i> , 2020, 12, 11.	6.1	92
68	Diagnostic approaches of pneumonia for commercial-scale biomedical applications: an overview. <i>International Journal of Transgender Health</i> , 2020, 13, 532-547.	2.3	3
69	Assessment of the Accuracy of Using ICD-9 Diagnosis Codes to Identify Pneumonia Etiology in Patients Hospitalized With Pneumonia. <i>JAMA Network Open</i> , 2020, 3, e207750.	5.9	22
70	Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies. <i>International Journal of COPD</i> , 2020, Volume 15, 2889-2900.	2.3	14
71	Investigational and Experimental Drugs for Community-Acquired Pneumonia: the Current Evidence. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 529-538.	3.2	9
72	Marijuana use and pneumonia risk in a cohort of HIV-infected and HIV-uninfected men. <i>Annals of Epidemiology</i> , 2020, 52, 64-70.e2.	1.9	3
73	Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	6

#	ARTICLE	IF	CITATIONS
74	A multiplex polymerase chain reaction assay for antibiotic stewardship in suspected pneumonia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115179.	1.8	25
75	COVID-19 and clinical neuropsychology: A review of neuropsychological literature on acute and chronic pulmonary disease. <i>Clinical Neuropsychologist</i> , 2020, 34, 1480-1497.	2.3	18
76	Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin. <i>Clinical Drug Investigation</i> , 2020, 40, 947-960.	2.2	20
77	Community-Acquired Pneumonia. <i>Journal of Infusion Nursing</i> , 2020, 43, 187-190.	2.3	0
78	Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial—a trial protocol. <i>Trials</i> , 2020, 21, 727.	1.6	2
79	The Burden of Community-Acquired Pneumonia Requiring Admission to an ICU in the United States. <i>Chest</i> , 2020, 158, 841-843.	0.8	1
80	Impact of a pharmacist-driven azithromycin de-escalation initiative for community-acquired pneumonia. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, , .	1.0	0
81	Mechanism and inhibition of <i>Streptococcus pneumoniae</i> IgA1 protease. <i>Nature Communications</i> , 2020, 11, 6063.	12.8	14
82	Factors Associated with In-Hospital Mortality in Acute Care Hospital Settings: A Prospective Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7951.	2.6	4
83	Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines. <i>Vaccine</i> , 2020, 38, 7747-7755.	3.8	9
84	Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	119
85	D-dimer as A Biomarker of Severity and Adverse Outcomes in Patients with Community Acquired Pneumonia. <i>Archives of Medical Research</i> , 2020, 51, 429-435.	3.3	9
86	The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. <i>Chest</i> , 2020, 158, 1008-1016.	0.8	46
87	Pneumonia risk and its associated factors in Parkinson's disease: A National Database Study. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116949.	0.6	14
88	Lefamulin: The First Systemic Pleuromutilin Antibiotic. <i>Annals of Pharmacotherapy</i> , 2020, 54, 1203-1214.	1.9	15
89	Alcohol Use Disorders Are Associated With a Unique Impact on Airway Epithelial Cell Gene Expression. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1571-1584.	2.4	2
90	Association of meteorological factors and atmospheric particulate matter with the incidence of pneumonia: an ecological study. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1676-1683.	6.0	14
91	Blind Spots of Traditional Microbiological Tests for Severe Community-Acquired Pneumonia in Adults and Availability of Nonculture Techniques: A Nationwide Survey of Physicians in China. <i>Journal of Infectious Diseases</i> , 2020, 221, S198-S205.	4.0	2

#	ARTICLE	IF	CITATIONS
92	Identifying Clinical Research Priorities in Adult Pulmonary and Critical Care. NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 511-523.	5.6	40
93	Community-acquired pneumonia in chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases, 2020, 33, 173-181.	3.1	24
94	Burden of Adults Hospitalized With Group B Streptococcal Infection. Journal of Infectious Diseases, 2021, 224, 1170-1178.	4.0	11
95	Predictive Value of the Neutrophil-to-Lymphocyte Ratio for the Diagnosis of Pneumonia in Normothermic Dyspneic Patients with Chronic Heart Failure in the Emergency Department. Journal of Emergency Medicine, 2020, 58, 892-901.	0.7	1
96	Socioeconomic Position and the Incidence, Severity, and Clinical Outcomes of Hospitalized Patients With Community-Acquired Pneumonia. Public Health Reports, 2020, 135, 364-371.	2.5	19
97	Upper respiratory tract colonization with <i>Streptococcus pneumoniae</i> in adults. Expert Review of Vaccines, 2020, 19, 353-366.	4.4	31
98	Association between ambient fine particulate matter and adult hospital admissions for pneumonia in Beijing, China. Atmospheric Environment, 2020, 231, 117497.	4.1	9
99	Other Respiratory Viruses as a Cause of Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 579-591.	2.1	2
100	The aetiology of severe community-acquired pneumonia requiring intensive care unit admission in the Western Cape. African Journal of Thoracic and Critical Care Medicine, 2020, 26, 5.	0.6	1
101	Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Advances in Therapy, 2020, 37, 1302-1318.	2.9	100
102	Qualification and Clinical Validation of an Immunodiagnostic Assay for Detecting 11 Additional <i>Streptococcus pneumoniae</i> Serotype-specific Polysaccharides in Human Urine. Clinical Infectious Diseases, 2020, 71, e430-e438.	5.8	23
103	Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. American Journal of Preventive Medicine, 2020, 58, 487-495.	3.0	9
104	Molecular Imaging of Pulmonary Inflammation and Infection. International Journal of Molecular Sciences, 2020, 21, 894.	4.1	18
106	Elevated body mass index is associated with an increased risk of infectious disease admissions and mortality: a mendelian randomization study. Clinical Microbiology and Infection, 2021, 27, 710-716.	6.0	13
107	Aetiology and antimicrobial susceptibility pattern of bacterial isolates in community acquired pneumonia patients at Asir region, Saudi Arabia. International Journal of Clinical Practice, 2021, 75, e13667.	1.7	10
108	Updates on community acquired pneumonia management in the ICU. , 2021, 217, 107663.		68
109	Validation of a Community-Acquired Pneumonia Score To Improve Empiric Antibiotic Selection at an Academic Medical Center. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
110	Identification of <i>Streptococcus pneumoniae</i> in hospital-acquired pneumonia in adults. Journal of Hospital Infection, 2021, 108, 146-157.	2.9	18

#	ARTICLE	IF	CITATIONS
111	Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Community-Acquired Pneumonia. <i>Annals of Emergency Medicine</i> , 2021, 77, e1-e57.	0.6	4
112	Pneumonia in older adults. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 135-141.	3.1	8
113	Community-acquired pneumonia: Trends in and research on drug resistance and advances in new antibiotics. <i>BioScience Trends</i> , 2021, 15, 266-275.	3.4	3
114	Predicting the Need for ICU Admission in COVID-19 Patients Using XGBoost. <i>Computers, Materials and Continua</i> , 2021, 69, 2077-2092.	1.9	0
115	Association between body mass index and mortality in hospitalised patients with community-acquired pneumonia. <i>ERJ Open Research</i> , 2021, 7, 00736-2020.	2.6	13
116	Effect of Soluble CD14 Subtype (sCD14ST)/ Presepsin and Lactate Clearance on Mortality Status In Pneumonia Patients With Sepsis. <i>Respiratory Science</i> , 2021, 1, 116-131.	0.1	0
117	Risk Factors for Pneumonia and Death in Adult Patients With Seasonal Influenza and Establishment of Prediction Scores: A Population-Based Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab068.	0.9	10
118	Incidence of lung cancer following pneumonia in smokers: a population-based study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.5	2
119	Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature. <i>Journal of Pharmacy Technology</i> , 2021, 37, 152-160.	1.0	4
121	A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant <i>S. pneumoniae</i> in Ambulatory and Hospitalized Adult Patients in the United States. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab063.	0.9	24
122	Pneumococcal pneumonia in adult hospitalised solid organ transplant recipients: Nationwide, population-based surveillance. <i>International Journal of Clinical Practice</i> , 2021, 75, e14126.	1.7	2
123	Risk factors for 3-month mortality in bedridden patients with hospital-acquired pneumonia: A multicentre prospective study. <i>PLoS ONE</i> , 2021, 16, e0249198.	2.5	9
124	Never Let a Good Crisis Go to Waste. <i>Chest</i> , 2021, 159, 917-919.	0.8	5
125	Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 295-313.	3.1	9
126	In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
127	Clinical Features and Outcomes of Community-Acquired Pneumonia Caused by <i>Haemophilus influenzae</i> . <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa622.	0.9	3
128	Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation. <i>Clinical Therapeutics</i> , 2021, , .	2.5	5
129	What Fraction of Adult Community-Acquired Pneumonia Is Caused by the <i>Pneumococcus</i> ? New Insights from Spain. <i>Clinical Infectious Diseases</i> , 2021, 73, 1086-1088.	5.8	0

#	ARTICLE	IF	CITATIONS
130	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011â€“2018. <i>Clinical Infectious Diseases</i> , 2021, 73, 1075-1085.	5.8	31
131	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021, 7, 25.	30.5	230
132	The effect of air temperature on hospital admission of adults with community acquired pneumonia in Baotou, China. <i>Scientific Reports</i> , 2021, 11, 9353.	3.3	3
133	Thrombospondin-1 Restricts Interleukin-36Î³-Mediated Neutrophilic Inflammation during <i>Pseudomonas aeruginosa</i> Pulmonary Infection. <i>MBio</i> , 2021, 12, .	4.1	15
134	The effect of immunomodulators on various markers of the acute inflammation phase in patients with mild community-acquired pneumonia. <i>Tuberculosis and Lung Diseases</i> , 2021, 99, 36-43.	0.7	0
135	COVID-19 from the interdisciplinary standpoint. Round table. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2849.	1.4	6
136	Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 34.	2.9	0
138	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 1216-1222.	5.8	33
139	Effects of CNS Injury-Induced Immunosuppression on Pulmonary Immunity. <i>Life</i> , 2021, 11, 576.	2.4	1
140	Pediatriciansâ€™ Compliance to the Clinical Management Guidelines for Community-Acquired Pneumonia in Infants and Young Children in Pakistan. <i>Healthcare (Switzerland)</i> , 2021, 9, 701.	2.0	3
141	Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab135.	0.9	4
142	Risk factors of community acquired pneumonia among the elderly population: A study in a semi urban area. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2021, 6, 125-129.	0.1	0
143	The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. <i>Expert Review of Vaccines</i> , 2021, 20, 691-705.	4.4	14
144	Burden of Respiratory Infection and Tuberculosis Among US States from 1990 to 2019. <i>Clinical Epidemiology</i> , 2021, Volume 13, 503-514.	3.0	3
145	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1087-1097.	3.2	17
146	Clinical characteristics and outcomes of community-acquired pneumonia in western Saudi Arabia: A four-year retrospective analysis of medical records. <i>Journal of Infection and Public Health</i> , 2021, 14, 960-966.	4.1	5
147	Real-time interactive artificial intelligence of thingsâ€‘based prediction for adverse outcomes in adult patients with pneumonia in the emergency department. <i>Academic Emergency Medicine</i> , 2021, 28, 1277-1285.	1.8	13
148	Mortality and readmission in the year following hospitalization for pneumonia among US adults. <i>Respiratory Medicine</i> , 2021, 185, 106476.	2.9	13

#	ARTICLE	IF	CITATIONS
149	Clinical Outcomes of Immunocompromised Adults Hospitalized with Pneumococcal Pneumonia: A Case-Control Study. <i>Microorganisms</i> , 2021, 9, 1746.	3.6	0
150	Heparin-based blood purification attenuates organ injury in baboons with <i>Streptococcus pneumoniae</i> pneumonia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L321-L335.	2.9	4
151	Variation in COVID-19 disease severity at hospital admission over time and across hospitals. <i>Medicine (United States)</i> , 2021, 100, e27265.	1.0	3
152	A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. <i>Expert Review of Vaccines</i> , 2021, 20, 1311-1325.	4.4	7
153	Value of Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Red Blood Cell Distribution Width in Evaluating the Prognosis of Children with Severe Pneumonia. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-8.	1.2	6
154	Part I: Interactive case: Strategies for antimicrobial optimization. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1179-1184.	1.0	0
155	Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 836-845.	4.0	24
156	Clinical Evaluation of a Metagenomics-Based Assay for Pneumonia Management. <i>Frontiers in Microbiology</i> , 2021, 12, 751073.	3.5	24
157	The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia. <i>BMC Infectious Diseases</i> , 2021, 21, 949.	2.9	11
158	Pharmacokinetics of tigecycline in both plasma and sputum in patients with severe pneumonia. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 1-3.	2.2	2
159	Community-acquired pneumonia. <i>Lancet, The</i> , 2021, 398, 906-919.	13.7	82
160	Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2232-2240.	3.3	1
162	Differential Diagnosis of Types of Pneumonia in the Elderly. , 2020, , 35-66.		3
163	One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults. <i>Clinical Infectious Diseases</i> , 2021, 73, 283-290.	5.8	20
165	<i>Streptococcus pneumoniae</i> : Invasion and Inflammation. , 0, , 316-330.		6
166	Incidence rate of community-acquired pneumonia in adults: a population-based prospective active surveillance study in three cities in South America. <i>BMJ Open</i> , 2018, 8, e019439.	1.9	28
167	Community-Acquired Pneumonia: A Focused Review. <i>American Journal of Medical Case Reports</i> , 2020, 9, 45-52.	0.2	25
168	Clinical Guideline Highlights for the Hospitalist: 2019 American Thoracic Society/Infectious Diseases Society of America Update on Community-Acquired Pneumonia. <i>Journal of Hospital Medicine</i> , 2020, 15, 743-745.	1.4	7

#	ARTICLE	IF	CITATIONS
169	Epidemiologic Survey of <i>Legionella</i> Urine Antigen Testing Within a Large Wisconsin-Based Health Care System. Journal of Patient-centered Research and Reviews, 2020, 7, 165-175.	0.9	3
170	Pneumococcal disease burden from an Indian perspective: Need for its prevention in pulmonology practice. Lung India, 2019, 36, 216.	0.7	13
171	Successfully non-surgical management of flail chest as first manifestation of multiple myeloma: A case report. World Journal of Critical Care Medicine, 2019, 8, 59-63.	1.8	36
172	Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. World Journal of Critical Care Medicine, 2019, 8, 74-96.	1.8	40
173	Pulmonary Infections, Including Ventilator-Associated Pneumonia. Critical Care Nursing Clinics of North America, 2021, 33, 381-393.	0.8	1
174	Influence of LncRNA NKILA on Bloodstream Infection of Hypervirulent Klebsiella pneumoniae and Its Ability to Induce Delayed Neutrophil Apoptosis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-10.	1.2	2
175	Toplum kâŕkenli pnŕmoniye neden olan etkenler ve mortalitenin deŕlendirilmesi. Pamukkale Medical Journal, 0, , .	0.2	0
176	Impact of a pharmacistŕled pneumococcal vaccination outreach program in a primary care setting. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 302-309.	1.0	2
177	Community-Acquired Pneumonia (CAP). , 2017, , .		0
179	Acute Kidney Injury in patients with pneumonia. Rossijskij Mediko-socialŕnyj Ŗŕurnal, 2019, 1, 59-73.	0.0	4
180	Clinical Progress Note: Procalcitonin in the Diagnosis and Management of CommunityŕAcquired Pneumonia in Hospitalized Adults. Journal of Hospital Medicine, 2019, 14, 691-693.	1.4	1
182	NITRIC OXIDE METABOLISM IN PATIENTS WITH COMMUNITYACQUIRED PNEUMONIA ASSOCIATED WITH CORONARY HEART DISEASE AND THE POSSIBILITY OF ITS MEDICAMENTOUS MANAGEMENT. Wiadomoŕci Lekarskie, 2020, 73, 1707-1711.	0.3	6
183	Pneumonia Caused by Three Separate Microorganisms Simultaneously in a Patient Infected with Human Immunodeficiency Virus. Cureus, 2020, 12, e7804.	0.5	0
184	Treatment and outcomes among patients ŕ85 years hospitalized with community-acquired pneumonia. Journal of Investigative Medicine, 2021, , jim-2021-002078.	1.6	0
185	Emergency Imaging of Thoracic Infections and Complications. Seminars in Roentgenology, 2021, 57, 30-39.	0.6	0
186	Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review. Journal of International Medical Research, 2021, 49, 030006052110499.	1.0	2
187	Artificial Intelligence Applied to Chest X-Ray Images for the Automatic Detection of COVID-19. A Thoughtful Evaluation Approach. IEEE Access, 2020, 8, 226811-226827.	4.2	70
188	Clinical and microbiological profile of adult inpatients with community acquired pneumonia in Ilorin, North Central, Nigeria. African Health Sciences, 2020, 20, 1655-68.	0.7	7

#	ARTICLE	IF	CITATIONS
189	Short-term exposure to fine particulate matter and pneumonia-related hospitalizations: a systematic review and meta-analysis. <i>Environmental Research Letters</i> , 2020, 15, 123012.	5.2	2
190	Community-acquired bacterial pneumonia in adults: An update. <i>Indian Journal of Medical Research</i> , 2020, 151, 287.	1.0	39
192	Clinical Analysis of Sputum Gram Stains and Cultures to Improve the Quality of Sputum Cultures. <i>Journal of Laboratory Medicine and Quality Assurance</i> , 2020, 42, 33-39.	0.4	1
193	Antibiotic Treatment of Pulmonary Infections: An Umbrella Review and Evidence Map. <i>Frontiers in Pharmacology</i> , 2021, 12, 680178.	3.5	2
194	Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia. <i>Chest</i> , 2022, 161, 927-936.	0.8	22
195	Prone position nursing combined with ECMO intervention prevent patients with severe pneumonia from complications and improve cardiopulmonary function. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 4969-4977.	0.0	0
196	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 271-279.	2.9	1
197	Inflammation, ageing and diseases of the lung: Potential therapeutic strategies from shared biological pathways. <i>British Journal of Pharmacology</i> , 2022, 179, 1790-1807.	5.4	8
198	Electrocardiographic abnormalities in COVID-19 patients visiting the emergency department: a multicenter retrospective study. <i>BMC Emergency Medicine</i> , 2021, 21, 141.	1.9	11
199	Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 3229-3237.	2.3	5
200	Role of blood urea nitrogen and serum albumin ratio in predicting severity of community acquired pneumonia (CAP). <i>Monaldi Archives for Chest Disease</i> , 2021, , .	0.6	5
201	Case management in a <scp>COVID</scp>-19 surge: A <scp>singleâ€institution</scp> study of disposition and access to <scp>postâ€acute</scp> care. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 372-375.	2.6	1
202	A click chemistry approach to pleuromutilin derivatives, evaluation of anti-MRSA activity and elucidation of binding mode by surface plasmon resonance and molecular docking. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 2087-2103.	5.2	10
203	Clinical outcomes in patients with COPD hospitalized with SARS-CoV-2 versus non- SARS-CoV-2 community-acquired pneumonia. <i>Respiratory Medicine</i> , 2022, 191, 106714.	2.9	7
204	Cost-effectiveness of vaccination of elderly citizens against pneumococcal infection in the Russian Federation. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 41.	0.6	3
206	All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 853-867.	1.4	3
207	Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA. <i>Infectious Diseases and Therapy</i> , 2022, 11, 987-999.	4.0	5
208	Impact of a dental care intervention on the hospital mortality of critically ill patients admitted to intensive care units: A quasi-experimental study. <i>American Journal of Infection Control</i> , 2022, 50, 1156-1161.	2.3	4

#	ARTICLE	IF	CITATIONS
209	A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada. <i>Vaccine</i> , 2022, 40, 1047-1053.	3.8	3
210	Noninvasive ventilation improves the outcome in patients with pneumonia-associated respiratory failure: Systematic review and meta-analysis. <i>Journal of Infection and Public Health</i> , 2022, 15, 349-359.	4.1	8
211	Recruitment and training of alveolar macrophages after pneumococcal pneumonia. <i>JCI Insight</i> , 2022, 7, .	5.0	12
212	Severe community-acquired pneumonia in adults. Clinical recommendations from Russian Federation of Anaesthesiologists and Reanimatologists. <i>Russian Journal of Anesthesiology and Reanimatology /Anesteziologiya i Reanimatologiya</i> , 2022, , 6.	0.7	10
213	Diagnostic role of internal mammary lymph node involvement in tuberculous pleurisy: a multicenter study. <i>Pulmonology</i> , 2022, , .	2.1	3
214	Functional and structural impairments of the pulmonary system in middle-aged people with cervical and upper thoracic spinal cord injuries. <i>Journal of Spinal Cord Medicine</i> , 2023, 46, 732-741.	1.4	1
215	Short-Term Readmission Following Community-Acquired Pneumonia: A Cross-Sectional Study. <i>Hospital Pharmacy</i> , 2022, 57, 712-720.	1.0	1
216	Response to Vyse et al., "A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK" Expert Review of Vaccines, 2022, , 1-2.	4.4	1
217	23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i> . <i>Microorganisms</i> , 2022, 10, 560.	3.6	18
218	Effectiveness of angiotensin converting enzyme inhibitors in preventing pneumonia: A systematic review and meta-analysis. <i>Journal of General and Family Medicine</i> , 0, , .	0.8	3
219	To Thicken or Not to Thicken: Exploring the Use of Math-Based Clinical Decision Making. <i>Perspectives of the ASHA Special Interest Groups</i> , 0, , 1-13.	0.8	0
220	Vaccine-preventable disease hospitalized patients with heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, 474-481.	1.8	4
221	A Pragmatic, Stepped-Wedge, Cluster-controlled Clinical Trial of Real-Time Pneumonia Clinical Decision Support. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1330-1336.	5.6	11
222	The hospitalization burden of all-cause pneumonia in China: A population-based study, 2009-2017. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 22, 100443.	2.9	7
223	Bacterial pneumonia and subsequent dementia risk: A nationwide cohort study. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 12-18.	4.1	10
224	Application of Internet of Things in Chronic Respiratory Disease Prevention, Diagnosis, Treatment and Management. <i>Clinical EHealth</i> , 2022, 5, 10-16.	7.5	5
225	How Would You Treat This Patient Hospitalized With Community-Acquired Pneumonia?. <i>Annals of Internal Medicine</i> , 2021, 174, 1719-1726.	3.9	1
226	Clinical importance of determination of procalcitonin in diagnosis of sepsis. <i>Medical Alphabet</i> , 2021, , 30-34.	0.2	0

#	ARTICLE	IF	CITATIONS
227	Promising Expectations for Pneumococcal Vaccination during COVID-19. <i>Vaccines</i> , 2021, 9, 1507.	4.4	6
228	Risk of community acquired pneumonia in patients with diabetes mellitus: Review. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 448-453.	0.8	1
229	Age- and sex-related differences in community-acquired pneumonia at presentation to the emergency department: a retrospective cohort study. <i>European Journal of Emergency Medicine</i> , 0, Publish Ahead of Print, .	1.1	0
230	Incidence, aetiology and serotype coverage for pneumococcal vaccines of community-acquired pneumonia in adults: a population-based prospective active surveillance study in Brazil. <i>BMJ Open</i> , 2022, 12, e059824.	1.9	4
231	Comparison between the Severity Scoring Systems A-DROP and CURB-65 for Predicting Safe Discharge from the Emergency Department in Patients with Community-Acquired Pneumonia. <i>Emergency Medicine International</i> , 2022, 2022, 1-8.	0.8	5
232	Urgent need for a rapid microbiological diagnosis in critically ill pneumonia. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 6-14.	1.3	2
233	Neutrophilâ€“lymphocyte ratio as a predictor of adverse outcome in patients with communityâ€“acquired pneumonia: A systematic review. <i>Health Science Reports</i> , 2022, 5, e630.	1.5	11
234	Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 30, 1-9.	2.2	3
235	Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital. <i>Scientific Reports</i> , 2022, 12, .	3.3	11
236	Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia. <i>Medicine (United States)</i> , 2022, 101, e29159.	1.0	0
237	Pathogenesis of pneumonia and acute lung injury. <i>Clinical Science</i> , 2022, 136, 747-769.	4.3	53
238	Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	43
239	Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 â€“ April 2019. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	7
240	Communityâ€“acquired pneumonia and its predictors of mortality in rural southwestern Nigeria: Aâ€“five year retrospective observational study. <i>African Journal of Emergency Medicine</i> , 2022, 12, 293-297.	1.1	1
242	Federal guidelines on diagnosis and treatment of community-acquired pneumonia. <i>Pulmonologiya</i> , 2022, 32, 295-355.	0.8	10
243	Evaluation of the Effect of Comorbidity on the Efficacy and Safety of Î²-Lactam Antibiotics in Patients with Community-Acquired Pneumonia. <i>Safety and Risk of Pharmacotherapy</i> , 2022, 10, 96-109.	0.2	0
244	Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	5
245	Comparison of Chest Radiograph Impressions for Diagnosing Pneumonia: Accounting for Categories of Language Certainty. <i>Journal of the American College of Radiology</i> , 2022, 19, 1130-1137.	1.8	2

#	ARTICLE	IF	CITATIONS
246	Aetiology and prognosis of community-acquired pneumonia at the Adult University Teaching Hospital in Zambia. PLoS ONE, 2022, 17, e0271449.	2.5	6
247	Clinical risk factors for admission with Pseudomonas and multidrug-resistant Pseudomonas community-acquired pneumonia. Antimicrobial Resistance and Infection Control, 2022, 11, .	4.1	4
248	Rectal microbiota are coupled with altered cytokine production capacity following community-acquired pneumonia hospitalization. IScience, 2022, , 104740.	4.1	1
249	LncRNA SNHG16 is Downregulated in Pneumonia and Downregulates miR-210 to Promote LPS-Induced Lung Cell Apoptosis. Molecular Biotechnology, 0, , .	2.4	1
250	Association of Serum Albumin and Copeptin with Early Clinical Deterioration and Instability in Community-Acquired Pneumonia. Advances in Respiratory Medicine, 2022, 90, 323-337.	1.0	1
251	Development and Validation of a Sensitive and Robust Multiplex Antigen Capture Assay to Quantify Streptococcus pneumoniae Serotype-Specific Capsular Polysaccharides in Urine. MSphere, 2022, 7, .	2.9	5
252	Pneumonia and Related Conditions in Critically Ill Patientsâ€™ Insights from Basic and Experimental Studies. International Journal of Molecular Sciences, 2022, 23, 9896.	4.1	2
253	Differential impact of systolic and diastolic heart failure on in-hospital treatment, outcomes, and cost of patients admitted for pneumonia. , 2023, 9, 100025.		0
254	Reduced plasma levels of RGM-A predict stroke-associated pneumonia in patients with acute ischemic stroke: A prospective clinical study. Frontiers in Neurology, 0, 13, .	2.4	1
255	Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group. Respiratory Research, 2022, 23, .	3.6	12
256	Incorporation of Suppression of Tumorigenicity 2 into Random Survival Forests for Enhancing Prediction of Short-Term Prognosis in Community-ACQUIRED Pneumonia. Journal of Clinical Medicine, 2022, 11, 6015.	2.4	0
257	How and when to manage respiratory infections out of hospital. European Respiratory Review, 2022, 31, 220092.	7.1	7
258	Pneumonia and Pulmonary Thromboembolism Classification Using Electronic Health Records. Diagnostics, 2022, 12, 2536.	2.6	0
259	Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Internal and Emergency Medicine, 2022, 17, 2279-2290.	2.0	2
260	Prevalence, Incidence, and Severity Associated with Viral Respiratory Tract Infections in Colombian adults before the COVID-19 Pandemic. Journal of Infection and Public Health, 2022, , .	4.1	0
261	Aetiology, Clinical Presentation and Outcome in Patients with Community-Acquired Pneumonia Requiring Hospitalisation: A Prospective Study. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 62, 117-125.	0.1	0
262	Prevalence of new-onset atrial fibrillation in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Internal and Emergency Medicine, 2023, 18, 127-135.	2.0	9
263	Community-acquired pneumonia in hospitalised patients: changes in aetiology, clinical presentation, and severity outcomes in a 10-year period. Annals of Medicine, 2022, 54, 3052-3059.	3.8	0

#	ARTICLE	IF	CITATIONS
264	Machine learning methods to predict 30-day hospital readmission outcome among US adults with pneumonia: analysis of the national readmission database. BMC Medical Informatics and Decision Making, 2022, 22, .	3.0	3
265	Cost-Effectiveness of Pneumococcal Vaccination among Patients with Diabetes Mellitus. Epidemiologiya I Vaktsinoprofilaktika, 2022, 21, 78-88.	0.8	2
266	Antibiotic treatment of community-acquired pneumonia. , 2022, 1, 34-38.		0
267	A Novel Index in the Prediction of Pneumonia Following Acute Ischemic Stroke. International Journal of Environmental Research and Public Health, 2022, 19, 15306.	2.6	3
268	Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 14959.	4.1	42
269	Prevalence and characteristics of antibiotic prescription for acute COVID-19 patients in Japan. Scientific Reports, 2022, 12, .	3.3	3
270	Characteristics, Management, and Outcomes of Community-Acquired Pneumonia Due to Human Rhinovirusâ€”A Retrospective Study. Canadian Respiratory Journal, 2022, 2022, 1-8.	1.6	3
271	Hospital Admission Decisions for Older Veterans with Communityâ€”onset Pneumonia: An Analysis of 118 U.S. Veterans Affairs Medical Centers.. Academic Emergency Medicine, 0, .	1.8	0
272	Peak expiratory flow, but not tongue pressure, can predict pneumonia development in older adults. European Geriatric Medicine, 2023, 14, 211-217.	2.8	5
273	Obese Mice with Pneumonia Have Hyperleptinemia and Increased Pulmonary Signal Transducer and Activator of Transcription 3 Activation. Shock, 0, Publish Ahead of Print, .	2.1	0
274	Clarithromycin for community-acquired pneumonia in adults: focus on anti-inflammatory properties. Terapevticheskii Arkhiv, 2023, 94, 1394-1400.	0.8	0
275	Increased Risk of Hospitalization for Pneumonia in Italian Adults from 2010 to 2019: Scientific Evidence for a Call to Action. Vaccines, 2023, 11, 187.	4.4	3
277	TLRs Gene Polymorphisms Associated with Pneumonia before and during COVID-19 Pandemic. Diagnostics, 2023, 13, 121.	2.6	4
278	The Impact of Nonalcoholic Fatty Liver Disease on Severe Community-Acquired Pneumonia Outcomes. Life, 2023, 13, 36.	2.4	3
279	A Multi-Center Clinical Trial for Wireless Stethoscope-Based Diagnosis and Prognosis of Children Community-Acquired Pneumonia. IEEE Transactions on Biomedical Engineering, 2023, 70, 2215-2226.	4.2	3
280	Agreement of respiratory viruses' detection between nasopharyngeal swab and bronchoalveolar lavage in adults admitted for pneumonia: a retrospective study. Clinical Microbiology and Infection, 2023, 29, 942.e1-942.e6.	6.0	3
281	Carriage prevalence, serotype distribution, antimicrobial resistance, pspA typing and pilus islets of Streptococcus pneumoniae isolated from adults living in a Brazilian urban slum. Vaccine, 2023, 41, 1431-1437.	3.8	2
282	Hydrocortisone in Severe Community-Acquired Pneumonia. New England Journal of Medicine, 2023, 388, 1931-1941.	27.0	105

#	ARTICLE	IF	CITATIONS
283	SLC38A6 expression in macrophages exacerbates pulmonary inflammation. Respiratory Research, 2023, 24, .	3.6	2
284	Pneumonia risk prediction in patients with acute alcohol withdrawal syndrome through evaluation of sarcopenia index as a prognostic factor. BMC Geriatrics, 2023, 23, .	2.7	0
285	The epidemiology and healthcare costs of community-acquired pneumonia in Ontario, Canada: a population-based cohort study. Journal of Medical Economics, 2023, 26, 293-302.	2.1	1
286	Characteristics, Outcomes, and Factors Affecting Mortality in Hospitalized Patients with CAP Due to Different Variants of SARS-CoV-2 and Non-COVID-19 CAP. Journal of Clinical Medicine, 2023, 12, 1388.	2.4	1
287	Treatment outcomes and its associated factors among pneumonia patients admitted to public hospitals in Harar, eastern Ethiopia: a retrospective follow-up study. BMJ Open, 2023, 13, e065071.	1.9	0
288	Advances in molecular diagnostic tests for community-acquired pneumonia. Minerva Respiratory Medicine, 2023, 62, .	0.2	0
289	The role of clinical models in understanding the etiology of pneumonia. Emergency Medicine, 2022, 18, 43-53.	0.2	0
290	CURB-65 and Long-Term Mortality of Community-Acquired Pneumonia: A Retrospective Study on Hospitalized Patients. Cureus, 2023, , .	0.5	0
291	Burden of Acute-Care Hospitalization for Community-Acquired Pneumonia in Canadian Adults Aged 50 Years or Older: Focusing on Most Responsible Diagnosis Tells Only Part of the Story. Vaccines, 2023, 11, 748.	4.4	0
292	In Patients Hospitalized for Community-Acquired Pneumonia, SARS-CoV-2 Is Associated with Worse Clinical Outcomes When Compared to Influenza. Pathogens, 2023, 12, 571.	2.8	1
294	Prevalence of atypical pathogens in patients with severe pneumonia: a systematic review and meta-analysis. BMJ Open, 2023, 13, e066721.	1.9	2
296	Evaluation of BioFire® FilmArray® Pneumonia Panel in Bronchoalveolar Lavage Samples From Immunocompromised Patients With Suspected Pneumonia. Cureus, 2023, , .	0.5	0
297	Community-Acquired Pneumonia Incidence in Adults Aged 18 Years and Older in Goto City, Japan. , 2023, 1, 100007.		1
298	Herd immunity in older adults from a middle-income country: A time-series trend analysis of community-acquired pneumonia mortality 2003-2017. Health Science Reports, 2023, 6, .	1.5	3
299	Clinical Effectiveness and Outcomes of Azithromycin versus Doxycycline Containing Regimen in Inpatients with Community Acquired Pneumonia: A Retrospective Cohort Study. Journal of Clinical Pharmacy and Therapeutics, 2023, 2023, 1-6.	1.5	0
301	Decreased community-acquired pneumonia coincided with rising awareness of precautions before governmental containment policy in Japan. , 2023, 2, .		0
302	Arginine concentration in arterial vs venous blood in a bleomycin-induced lung inflammation model in mice. PLoS ONE, 2023, 18, e0285770.	2.5	0
303	Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure. Kardiologiya, 2023, 63, 19-26.	0.7	1

#	ARTICLE	IF	CITATIONS
305	Methodological comparison of bronchoalveolar lavage fluid-based detection of respiratory pathogens in diagnosis of bacterium/fungus-associated pneumonia in critically ill patients. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	2
306	Respiratory fluoroquinolone monotherapy vs. β -lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Antimicrobial Agents</i> , 2023, 62, 106905.	2.5	3
307	Management of Pneumonia in Immunocompromised Patients. , 2023, , 1-31.		0
308	The prognostic value of rapid risk scores among patients with community-acquired pneumonia. <i>Wiener Klinische Wochenschrift</i> , 2023, 135, 507-516.	1.9	1
310	Treatment of Patients with Community-Acquired Pneumonia: Official Practice Guideline of the Infectious Diseases and Tropical Medicine Research Center Advisory Committee. <i>Archives of Clinical Infectious Diseases</i> , 2023, 18, .	0.2	0
311	Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2023, 13, e069013.	1.9	1
312	Respiratory Infections. <i>Clinics in Chest Medicine</i> , 2023, 44, 509-517.	2.1	0
314	Comparative Effectiveness of First-Line and Alternative Antibiotic Regimens in Hospitalized Patients With Nonsevere Community-Acquired Pneumonia. <i>Chest</i> , 2024, 165, 68-78.	0.8	2
316	The serotype-specific prevalence of pneumococci in hospitalized pneumonia patients with COPD: a prospective, multi-center, cohort study. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 714-724.	1.7	0
317	Hospital Admission Rates in Patients with COPD Throughout the COVID-19 Pandemic. <i>International Journal of COPD</i> , 0, Volume 18, 1763-1772.	2.3	0
319	Interventions to improve outcomes in community-acquired pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 0, , 1-16.	4.4	0
320	Reducing antimicrobial overuse through targeted therapy for patients with community-acquired pneumonia: a study protocol for a cluster-randomized factorial controlled trial (CARE-CAP). <i>Trials</i> , 2023, 24, .	1.6	0
321	Shifting Tides: Is It Time to Embrace Adjunctive Corticosteroids for Community-Acquired Pneumonia?. <i>Clinical Infectious Diseases</i> , 2023, 77, 1714-1716.	5.8	0
322	Organizational Benefits of Ultra-Low-Dose Chest CT Compared to Chest Radiography in the Emergency Department for the Diagnostic Workup of Community-Acquired Pneumonia: A Real-Life Retrospective Analysis. <i>Medicina (Lithuania)</i> , 2023, 59, 1508.	2.0	0
323	Identifying clusters of coexisting conditions and outcomes among adults admitted to hospital with community-acquired pneumonia: a multicentre cohort study. <i>CMAJ Open</i> , 2023, 11, E799-E808.	2.4	2
324	Pneumococcal Vaccine for Adults Aged ≥ 19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. <i>MMWR Recommendations and Reports</i> , 2023, 72, 1-39.	61.1	10
325	Guideline on treating community-acquired pneumonia with Chinese patent medicines. <i>Pharmacological Research</i> , 2023, 196, 106919.	7.1	1
327	Heparin-binding protein combined with human serum albumin in early assessment of community-acquired pneumonia: A retrospective study. <i>Journal of Acute Disease</i> , 2023, 12, 140.	0.3	0

#	ARTICLE	IF	CITATIONS
328	Compatibility of Omadacycline With Select Parenteral Products in Simulated Y-Site Administration. Clinical Therapeutics, 2023, , .	2.5	0
329	Efficacy and Safety of Corticosteroid Therapy for Community-Acquired Pneumonia: A Meta-Analysis and Meta-Regression of Randomized, Controlled Trials. Clinical Infectious Diseases, 2023, 77, 1704-1713.	5.8	4
330	Relationship between serum TNF- α , IL-6, and IL-10 levels and disease severity, and changes in the cytokines after treatment in patients with bacterial community-acquired pneumonia. Pneumon, 2023, 36, 1-8.	0.3	0
331	Risk of subsequent lower respiratory tract infection (LRTI) after hospitalization for COVID-19 LRTI and non-COVID-19 LRTI: a retrospective cohort study. Pneumonia (Nathan Qld), 2023, 15, .	6.1	0
332	β -Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients. Journal of Antimicrobial Chemotherapy, 0, , .	3.0	0
333	Acute phase reactants in non-COVID-19 community-acquired pneumonia. Egyptian Journal of Bronchology, 2023, 17, .	0.8	0
334	Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries. Open Forum Infectious Diseases, 2023, 10, .	0.9	3
335	Outcomes of patients admitted to the intensive care unit with community-acquired pneumonia in a tertiary care center in Riyadh, Saudi Arabia. Annals of Thoracic Medicine, 2023, 18, 206-210.	1.8	0
336	Efficacy of Raphamin against Pneumococcal Infection: a Preclinical Study. Bulletin of Experimental Biology and Medicine, 0, , .	0.8	0
337	Usefulness of a predictive model to hospitalize patients with low-risk community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 0, , .	2.9	0
338	Epidemiology of Pneumococcal Pneumonia in Louisville, Kentucky, and Its Estimated Burden of Disease in the United States. Microorganisms, 2023, 11, 2813.	3.6	1
339	Seeing through the MIST: A Pathway Towards Optimal Intervention for Pleural Infection. American Journal of Respiratory and Critical Care Medicine, 0, , .	5.6	0
340	Retrospective pharmaco-economic study of antibiotic therapy in community-acquired pneumonia. Farmakoekonomika, 2023, 16, 456-465.	1.2	0
341	Pathogenesis is the Basis of the Doctrine of Acute Pneumonia and the Principles of its Treatment. Journal of Pulmonology and Respiratory Research, 2023, 7, 028-031.	0.2	0
342	Community-Acquired Pneumonia in the Immunocompromised Host: Epidemiology and Outcomes. Open Forum Infectious Diseases, 2023, 10, .	0.9	0
344	Common Bacterial Infections during the 3-Month Period after SARS-CoV-2 Infection: A Retrospective Cohort Study. Healthcare (Switzerland), 2023, 11, 3151.	2.0	0
345	The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China. The Lancet Regional Health - Western Pacific, 2024, 42, 100968.	2.9	0
346	Does the "Obesity Paradox" Have an Expiration Date? A Retrospective Cohort Study. Journal of Clinical Medicine, 2023, 12, 6765.	2.4	0

#	ARTICLE	IF	CITATIONS
347	Nosocomial pneumonia. Medicinski Glasnik Specijalne Bolnice Za Bolesti Åtitaste Å½lezde I Bolesti Metabolizma Zlatibor, 2023, 28, 53-67.	0.1	0
348	ICU Utilization After Implementation of Minor Severe Pneumonia Criteria in Real-Time Electronic Clinical Decision Support. Critical Care Medicine, 2024, 52, e132-e141.	0.9	0
349	Toplumdan KazanÄ±lmÄ±ÅŸ PnÅŸmoni HastalarÄ±nda Prokalsitonin, C-Reaktif Protein, Kan Beyaz KÄ¼re SayÄ±larÄ±nÄ±n ve Hemogram Alt Parametrelerinin KarÄ±laÅŸtırÄ±lmasÄ±. Journal of Medicine and Palliative Care:, 2023, 4, 672-677.	0.2	0
350	Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants. Vaccine, 2024, 42, 573-582.	3.8	1
351	Development and validation of a predictive model for 30-day mortality in patients with severe community-acquired pneumonia in intensive care units. Frontiers in Medicine, 0, 10, .	2.6	0
352	Lysophosphatidylcholine acyltransferase level predicts the severity and prognosis of patients with community-acquired pneumonia: a prospective multicenter study. Frontiers in Immunology, 0, 14, .	4.8	0
353	Diagnostic and Prognostic Value of Peripheral Neutrophil CD64 Index in Elderly Patients with Community-Acquired Pneumonia. Critical Reviews in Immunology, 2024, 44, 79-89.	0.5	0
354	SARS-CoV-2 vs Streptococcus pneumoniae: a comparison of clinical features, laboratory findings, and clinical outcomes in patients hospitalized at Alessandriaâ€™s General Hospital. Working Paper of Public Health, 2023, 11, .	0.0	0
355	Influenza and Viral Pneumonia. Infectious Disease Clinics of North America, 2024, 38, 183-212.	5.1	0
356	Risk factors and predicting nomogram for the clinical deterioration of non-severe community-acquired pneumonia. BMC Pulmonary Medicine, 2024, 24, .	2.0	0
357	EMR Combined with CRB-65 Superior to CURB-65 in Predicting Mortality in Patients with Community-Acquired Pneumonia. Infection and Drug Resistance, 0, Volume 17, 463-473.	2.7	0
358	Plasma proteome analysis and validation of patients with communityâ€™acquired pneumonia: A cohort study. Proteomics - Clinical Applications, 0, , .	1.6	0
359	Socio-demographic and comorbid risk factors for poor prognosis in patients hospitalized with community-acquired bacterial pneumonia in southeastern US. Heart and Lung: Journal of Acute and Critical Care, 2024, 65, 31-39.	1.6	0
360	Long-Term Outcomes in Severe Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2024, 45, 266-273.	2.1	0
361	Lymphopenia is associated with broad host response aberrations in community-acquired pneumonia. Journal of Infection, 2024, 88, 106131.	3.3	0
362	Best Practices for Identifying Hospitalized Lower Respiratory Tract Infections Using Administrative Data: A Systematic Literature Review of Validation Studies. Infectious Diseases and Therapy, 2024, 13, 921-940.	4.0	0
363	Definition, Epidemiology, and Pathogenesis of Severe Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2024, 45, 143-157.	2.1	0
364	Associations between Present-on-Admission Do-Not-Resuscitate Orders and Short-Term Outcomes in Patients with Pneumonia. Southern Medical Journal, 2024, 117, 165-171.	0.7	0

#	ARTICLE	IF	CITATIONS
365	Optimizing Diagnosis and Management of Community-acquired Pneumonia in the Emergency Department. Emergency Medicine Clinics of North America, 2024, 42, 231-247.	1.2	0
366	Bacterial etiology of community-acquired pneumonia among adult patients in Ethiopia: A systematic review and meta-analysis. Heliyon, 2024, 10, e28008.	3.2	0